Experiment: 7P2O

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	2D 1H-15N HSQC	0.7 mM [U-99% 15N] SUD-C domain of SARS-CoV-2, 50 mM no sodium phosphate, 50 mM no sodium chloride, 2 mM no DTT, 2 mM no EDTA, 0.25 mM no DSS, 10 % no D2O	90% H2O/10% D2O	100 mM	7.2	1 atm	298	Bruker Avance HD- III HD 700
2	3D 1H-15N NOESY	0.7 mM [U-99% 15N] SUD-C domain of SARS-CoV-2, 50 mM no sodium phosphate, 50 mM no sodium chloride, 2 mM no DTT, 2 mM no EDTA, 0.25 mM no DSS, 10 % no D2O	90% H2O/10% D2O	100 mM	7.2	1 atm	298	Bruker Avance HD- III HD 700
8	3D HNHA	0.7 mM [U-99% 15N] SUD-C domain of SARS-CoV-2, 50 mM no sodium phosphate, 50 mM no sodium chloride, 2 mM no DTT, 2 mM no EDTA, 0.25 mM no DSS, 10 % no D2O	90% H2O/10% D2O	100 mM	7.2	1 atm	298	Bruker Avance HD- III HD 700
3	2D 1H-13C HSQC	0.7 mM [U-99% 15N] SUD-C domain of SARS-CoV-2, 50 mM no sodium phosphate, 50 mM no sodium chloride, 2 mM no DTT, 2 mM no EDTA, 0.25 mM no DSS, 10 % no D2O	90% H2O/10% D2O	100 mM	7.2	1 atm	298	Bruker Avance HD- III HD 700
4	3D HN(CA)CO	0.7 mM [U-99% 15N] SUD-C domain of SARS-CoV-2, 50 mM no sodium phosphate, 50 mM no sodium chloride, 2 mM no DTT, 2 mM no EDTA, 0.25 mM no DSS, 10 % no D2O	90% H2O/10% D2O	100 mM	7.2	1 atm	298	Bruker Avance HD- III HD 700
5	3D HN(CO)CA	0.7 mM [U-99% 15N] SUD-C domain of SARS-CoV-2, 50 mM no sodium phosphate, 50 mM no sodium chloride, 2 mM no DTT, 2 mM no EDTA, 0.25 mM no DSS, 10 % no D2O	90% H2O/10% D2O	100 mM	7.2	1 atm	298	Bruker Avance HD- III HD 700
6	3D HNCO	0.7 mM [U-99% 15N] SUD-C domain of SARS-CoV-2, 50 mM no sodium phosphate, 50 mM no sodium chloride, 2 mM no DTT, 2 mM no EDTA, 0.25 mM no DSS, 10 % no D2O	90% H2O/10% D2O	100 mM	7.2	1 atm	298	Bruker Avance HD- III HD 700
7	3D HNCA	0.7 mM [U-99% 15N] SUD-C domain of SARS-CoV-2, 50 mM no sodium phosphate, 50 mM no sodium chloride, 2 mM no DTT, 2 mM no EDTA, 0.25 mM no DSS, 10 % no D2O	90% H2O/10% D2O	100 mM	7.2	1 atm	298	Bruker Avance HD- III HD 700
9	3D HNCACB	0.7 mM [U-99% 15N] SUD-C domain of SARS-CoV-2, 50 mM no sodium phosphate, 50 mM no sodium chloride, 2 mM no DTT, 2 mM no EDTA, 0.25 mM no DSS, 10 % no D2O	90% H2O/10% D2O	100 mM	7.2	1 atm	298	Bruker Avance HD- III HD 700
10	3D HN(COCA)CB	0.7 mM [U-99% 15N] SUD-C domain of SARS-CoV-2, 50 mM no sodium phosphate, 50 mM no sodium chloride, 2 mM no DTT, 2 mM no EDTA, 0.25 mM no DSS, 10 % no D2O	90% H2O/10% D2O	100 mM	7.2	1 atm	298	Bruker Avance HD- III HD 700
11	3D HBHA(CO)NH	0.7 mM [U-99% 15N] SUD-C domain of SARS-CoV-2, 50 mM no sodium phosphate, 50 mM no sodium chloride, 2 mM no DTT, 2 mM no EDTA, 0.25 mM no DSS, 10 % no D2O	90% H2O/10% D2O	100 mM	7.2	1 atm	298	Bruker Avance HD- III HD 700
14	3D 1H-13C NOESY aliphatic	0.7 mM [U-99% 15N] SUD-C domain of SARS-CoV-2, 50 mM no sodium phosphate, 50 mM no sodium chloride, 2 mM no DTT, 2 mM no EDTA, 0.25 mM no DSS, 10 % no D2O	90% H2O/10% D2O	100 mM	7.2	1 atm	298	Bruker Avance HD- III HD 700
15	3D HCCH-TOCSY	0.7 mM [U-99% 15N] SUD-C domain of SARS-CoV-2, 50 mM no sodium phosphate, 50 mM no sodium chloride, 2 mM no DTT, 2 mM no EDTA, 0.25 mM no DSS, 10 % no D2O	90% H2O/10% D2O	100 mM	7.2	1 atm	298	Bruker Avance HD- III HD 700
16	3D 1H-13C NOESY aromatic	0.7 mM [U-99% 15N] SUD-C domain of SARS-CoV-2, 50 mM no sodium phosphate, 50 mM no sodium chloride, 2 mM no DTT, 2 mM no EDTA, 0.25 mM no DSS, 10 % no D2O	90% H2O/10% D2O	100 mM	7.2	1 atm	298	Bruker Avance HD- III HD 700

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	Avance HD- III HD	700

NMR Refinement
Method	Details	Software
molecular dynamics		Amber

NMR Ensemble Information
Conformer Selection Criteria	all calculated structures submitted
Conformers Calculated Total Number	20
Conformers Submitted Total Number	20
Representative Model	1 (minimized average structure)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	collection	TopSpin	3.2	Bruker Biospin
2	processing	TopSpin	3.2	Bruker Biospin
3	peak picking	CARA		Keller and Wuthrich
4	chemical shift assignment	CARA		Keller and Wuthrich
5	structure calculation	CYANA		Guntert, Mumenthaler and Wuthrich
6	refinement	Amber		Case, Darden, Cheatham III, Simmerling, Wang, Duke, Luo, ... and Kollman

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.